Trial reportPloS one2019
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis.Neurosurgical review · 2026Pooled it
- The concept, intention, and evaluation of the term treatment-refractory meningioma.Journal of neuro-oncology · 2025Pooled it
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Humanized antibody-drug conjugates for Somatostatin receptor 2 (SSTR2)-positive tumor treatment.Molecular cancer therapeutics · 2026Article
- New approaches to targeted drug therapy of intracranial tumors.Cell death discovery · 2025Review
- A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy.International journal of molecular sciences · 2025Review
- Review
- Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives.International journal of molecular sciences · 2023Article
- Hormone therapies in meningioma-where are we?Journal of neuro-oncology · 2023Review
- Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomasBiomedica : revista del Instituto Nacional de Salud · 2022Article
- Review
- Identification and Management of Aggressive Meningiomas.Frontiers in oncology · 2022Review
- Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma.International journal of molecular sciences · 2021Review
- Antibody-Drug Conjugate to Treat Meningiomas.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Case Report: Identification of a NovelFrontiers in oncology · 2021Article
- Cytotoxicity on low-grade canine meningioma with the use of somatostatin analog (octreotide): An in vitro study.Neuro-oncology advancesArticle
- A Case of Acromegaly With Parasellar Meningioma With Oculomotor Palsy Responding to and Maintained With Oral Octreotide Therapy.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas.
methods31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRβ and VEGFR2, their expression was correlated with outcomes.
resultsTwenty-two patients (72%) were female with a median age of 55 years (SD±15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95%CI 28.5-42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2-21.1) and 9.1 months (95%CI 6.8-16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFRβ and negative VEGFR2 expression were associated with longer survival both in OS and PFS.
conclusionSunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.